Fase 2

Quiénes somos

  • febrero 7, 2023
    A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer Without Liver Metastases
  • diciembre 8, 2022
    Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status
  • diciembre 8, 2022
    Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
  • diciembre 8, 2022
    Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer
  • diciembre 8, 2022
    Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer
  • diciembre 1, 2022
    Phase 2 Study of DKN-01 in Colorectal Cancer
  • septiembre 19, 2022
    A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors
  • 5 de abril de 2022
    Una vacuna (Ad5.F35-hGCC-PADRE) para el tratamiento del adenocarcinoma gastrointestinal
  • 5 de abril de 2022
    Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
  • 5 de abril de 2022
    A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer